MedTrace Logo

INCB018424 in Patients With Advanced Hematologic Malignancies

NCT00674479 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-06-15

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if ruxolitinib can help to control advanced hematological malignancies. The safety of this drug will also be studied.

Conditions

Interventions

DRUG

INCB018424

Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Farhad Ravandi-Kashani, M.D. · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-12
Primary Completion
2017-03-23
Completion
2017-03-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674479 on ClinicalTrials.gov